NCT04960618View on ClinicalTrials.gov

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Mycosis FungoidesMycosis Fungoides/Sezary SyndromeSezary SyndromeSézaryAdvanced Mycosis Fungoides
Interventions
DRUG

Gemcitabine

Participants will receive gemcitabine 1000 mg/m2 on days 1 and 8 on 21-days cycles for up to 6 cycles

DRUG

Pembrolizumab

Pembrolizumab 200 mg will be introduced with cycle 2 and will be given on day 1 of each 21-day cycle for up to 35 cycles

Trial Locations (8)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10032

RECRUITING

Columbia University, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER